Health Canada approves transfer of Otezla from Celgene Corporation to Amgen Canada.

Amgen Canada Inc.announced Health Canada’s approval of the Marketing Authorization transfer of Otezla (apremilast) from Celgene Corporation to Amgen Canada. This transfer is in line with Amgen Inc.’s previously announced acquisition of the worldwide rights to Otezla completed in November 2019. Otezla is approved in Canada for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and (alone or in combination with methotrexate) for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response, intolerance, or contraindication to a prior disease-modifying anti-rheumatic drug (DMARD).